ID   COV362 RRAS2 KO#41
AC   CVCL_E5L6
RX   PubMed=36476833;
CC   Population: Caucasian.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; HGNC:17271; RRAS2.
CC   Sequence variation: Mutation; HGNC; HGNC:1100; BRCA1; Simple; p.Pro871fs (c.2611_2612ins1); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1100; BRCA1; Simple; c.4095+1G>T; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2420 ! COV362
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=36476833; DOI=10.1038/s41388-022-02563-9; PMCID=PMC9883167;
RA   Clavain L., Fernandez-Pisonero M.I., Movilla N., Lorenzo-Martin L.F.,
RA   Nieto B., Abad A., Garcia-Navas R., Llorente-Gonzalez C.,
RA   Sanchez-Martin M., Vicente-Manzanares M., Santos E., Alarcon B.,
RA   Garcia-Aznar J.M., Dosil M., Bustelo X.R.;
RT   "Characterization of mutant versions of the R-RAS2/TC21 GTPase found
RT   in tumors.";
RL   Oncogene 42:389-405(2023).
//